Dr. Karmali Discusses Toxicites Associated With CAR T-Cell Therapies

Reem Karmali, MD
Published: Friday, Oct 20, 2017



Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the toxicities associated with the use of chimeric antigen receptor (CAR) T-cell therapies.

There are 2 main toxicities that experts are worried about, says Karmali—cytokine release syndrome and neurotoxicity. It is not yet clear what the mechanism is for neurotoxicity.

Karmali says that the patients being selected should have relatively preserved organ function so that they can withstand these toxicities.
 
SELECTED
LANGUAGE


Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the toxicities associated with the use of chimeric antigen receptor (CAR) T-cell therapies.

There are 2 main toxicities that experts are worried about, says Karmali—cytokine release syndrome and neurotoxicity. It is not yet clear what the mechanism is for neurotoxicity.

Karmali says that the patients being selected should have relatively preserved organ function so that they can withstand these toxicities.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x